Jim Van Heusden
Managing Director
Medigen Vaccine Biologics Co.
Belgium
Biography
Dr. Jim Van heusden has a unique background, combining his expertise derived from a successful drug discovery career within Janssen with a successful venture capital track record within Gimv. Jim’s most recent position was CEO of Karolinska Development, a publicly listed Nordic life science investment fund. He joined the company in 2015 to execute a strategic turnaround and reposition the company to become a leading Nordic life science investment company.
Research Interest
Prior to joining Gimv in 2001, he was working as a senior scientist at the department of Oncology Drug Discovery at Janssen Pharmaceutica, a Johnson & Johnson company, where he also served on the research management committee of the collaboration with Rigel Pharmaceuticals. He holds BSc and MSc degrees in chemistry and biochemistry from the University of Antwerp and a PhD in molecular and cellular biology from the University of Maastricht.
